SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Frequently asked questions
What sector does SQZ Biotechnologies Company (SQZB) operate in?
SQZ Biotechnologies Company belongs to the Healthcare sector and operates in the Biotechnology industry.
What is SQZ Biotechnologies Company (SQZB) current stock price?
As of the latest data, SQZ Biotechnologies Company stock price is $0.02, with a previous close of $0.02.
What is SQZ Biotechnologies Company (SQZB) current market capitalization?
SQZ Biotechnologies Company market cap is approximately 707.79 thousand.
What is SQZ Biotechnologies Company (SQZB) Earnings Per Share (EPS)?
The trailing EPS is -$2.08.
Does SQZ Biotechnologies Company (SQZB) pay dividends?
No. SQZ Biotechnologies Company does not pay a dividend.
What is SQZ Biotechnologies Company (SQZB) beta (volatility) score?
SQZ Biotechnologies Company has a beta of 0.383, indicating lower volatility than the overall market.